| Literature DB >> 21057897 |
Jaclyn Yoong1, Geoffrey Chong, K Hamilton.
Abstract
We report the case of a 59-year-old man with advanced renal cell carcinoma who developed bilateral papilledema while on therapy with sunitinib, a multi-targeted tyrosine kinase inhibitor (TKI). While papilledema has been reported in association with another TKI (imatinib), the association between sunitinib and papilledema has not previously been reported in the literature.Entities:
Mesh：
Substances：
Year: 2010 PMID： 21057897 DOI： 10.1007/s12032-010-9719-5
Source DB: PubMed Journal: Med Oncol ISSN： 1357-0560 Impact factor: 3.064